EUCTR2007-005166-12-DE进行中（未招募）不适用
A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine
Hutchison MediPharma Enterprises Limited0 个研究点目标入组 210 人开始时间: 2008年1月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Have active confirmed mild to moderate ulcerative colitis defined by a Mayo score 4-10, and with activity confirmed by study colonoscopy or sigmoidoscopy within 2 weeks prior to study entry.
- •2) Minimum Mayo endoscopy score of =1 at the time of study colonoscopy or sigmoidoscopy.
- •3) Age = 18 years
- •4) Have adequate renal, hepatic and bone marrow function (see exclusion criteria).
- •5) Female patients must be of non-childbearing potential defined as meeting at least one of the following criteria:
- •Age = 50 years and naturally amenorrhoeic for = 1 year*.
- •Premature ovarian failure confirmed by a specialist gynaecologist.
- •Previous bilateral salpingo-oophorectomy, or hysterectomy.
- •XY genotype, Turner’s syndrome, uterine agenesis.
- •*Amenorrhoea following cancer therapy does not rule out childbearing potential.
- •Fertile male and their partners must agree to use one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, oral contraceptive which has been started at least one month prior to visit one, contraceptive patch, or condom with spermicide during the study participation and within 3 months thereafter.
- •6) Show evidence of a personally signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial
- •7) May be on Mesalamine (or equivalent medications sulfasalazine, balsalazide, olsalazine) if they have been on it for at least 4 weeks prior to randomization, and the dose has been stable for = 2 weeks prior to randomization
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
- •1) Have active confirmed mild to moderate ulcerative colitis defined by a Mayo score 4-10, and with activity confirmed by study colonoscopy or sigmoidoscopy within 2 weeks prior to study entry.
- •2) Minimum Mayo endoscopy score of =1 at the time of study colonoscopy or sigmoidoscopy.
- •3) Age = 18 years
- •4) Have adequate renal, hepatic and bone marrow function (see exclusion criteria).
- •5) Female patients must be of non-childbearing potential defined as meeting at least one of the following criteria:
- •Age = 50 years and naturally amenorrhoeic for = 1 year*.
- •Premature ovarian failure confirmed by a specialist gynaecologist.
- •Previous bilateral salpingo-oophorectomy, or hysterectomy.
- •XY genotype, Turner’s syndrome, uterine agenesis.
- •*Amenorrhoea following cancer therapy does not rule out childbearing potential.
- •Fertile male and their partners must agree to use one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, oral contraceptive which has been started at least one month prior to visit one, contraceptive patch, or condom with spermicide during the study participation and within 3 months thereafter.
- •6) Show evidence of a personally signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial
- •7) May be on Mesalamine (or equivalent medications sulfasalazine, balsalazide, olsalazine) if they have been on it for at least 4 weeks prior to randomization, and the dose has been stable for = 2 weeks prior to randomization
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Diagnosed with Crohn’s Disease or with lesions such as fistulas or granulomas on biopsy noted either in history or at baseline endoscope which would be suspicious for Crohn’s disease, or with a diagnosis of indeterminant colitis;
- •2) Severe disease with an ulcerative colitis Mayo Clinical score above 10 points at baseline.
- •3) Positive stool test for pathogens on any one of three samples taken within the previous 2 weeks prior to study entry.
- •4) Toxic megacolon or toxic colitis
- •5) Probable requirement for intestinal surgery within 12 weeks after the start of study medication
- •6) Receiving oral or rectal steroids within 1 month prior to study entry.
- •7) Receiving rectal Mesalamine within one week prior to study entry
- •8) Receiving Azathioprine, 6 MP, or other immunosuppressive therapy including anti-TNF-a agents at the time of screening or within the preceding 6 weeks.
- •9) Receiving other investigational drugs or biologics within 1 month.
- •10) Receiving antibiotics within 2 week of study entry
- •11) Hemoglobin concentration < 9 g/dl
- •12) WBC below 3,000/cmm, or platelets below 100,000/cmm
- •13) SGOT, SGPT, alkaline phosphatase >2.5 upper limit of normal
- •14) Serum creatinine >1.5 times upper limit of normal
- •15) Significant concurrent medical diseases including: active peptic ulcer disease; uncompensated congestive heart disease; myocardial infarction within the last 12 months; unstable angina pectoris; uncontrolled hypertension; pulmonary disease requiring oxygen therapy.
- •16) Chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative) or any history of Hepatitis C.
- •17) Previous colonic surgery except for simple polypectomy.
- •18) History of cancer within the last 5 years other than resected cutaneous basal and squamous cell carcinomas, in situ cervical cancer and surgically removed colon polyps.
- •19) Women who are pregnant or breast feeding ;
- •20) Patients known to be seropositive for HIV, or who have had an AIDS defining illness, or a known immunodeficiency disorder
- •21) Patients with a history of tuberculosis or exposure to tuberculosis, or a history of a chest X ray suspicious for tuberculosis, unless shown to be PPD negative.
- •22) History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure;
- •23) Known allergy to plants of the Acanthaceae family;
- •24) Unwillingness to participate in the study;
- •25) Any underlying medical condition that in the Investigator’s opinion will make the administration of study drug hazardous to the patient or would obscure the interpretation of adverse events.
- •1) Diagnosed with Crohn’s Disease or with lesions such as fistulas or granulomas on biopsy noted either in history or at baseline endoscope which would be suspicious for Crohn’s disease, or with a diagnosis of indeterminant colitis;
- •2) Severe disease with an ulcerative colitis Mayo Clinical score above 10 points at baseline.
- •3) Positive stool test for pathogens on any one of three samples taken within the previous 2 weeks prior to study entry.
- •4) Toxic megacolon or toxic colitis
- •5) Probable requirement for intestinal surgery within 12 weeks after the start of study medication
- •6) Receiving oral or rectal steroids within 1 month prior to study entry.
- •7) Receiving rectal Mesalamine within one week prior to study entry
- •8) Receiving Azathioprine, 6 MP, or other immunosuppressive therapy including anti-TNF-a agents at the time of screening or within the preceding 6 weeks.
- •9) Receiving other investigational drugs or biologics within 1 month.
- •10) Receiving antibiotics within 2 week of study entry
- •11) Hemoglobin concentration < 9 g/dl
- •12) WBC below 3,000/cmm, or platelets below 100,000/cmm
- •13) SGOT, SGPT, alkaline phosphatase >2.5 upper limit of normal
- •14) Serum creatinine >1.5 times upper limit of normal
- •15) Significant concurrent medical diseases including: active peptic ulcer disease; uncompensated congestive heart disease; myocardial infarction within the last 12 months; unstable angina pectoris; uncontrolled hypertension; pulmonary disease requiring oxygen therapy.
- •16) Chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative) or any history of Hepatitis C.
- •17) Previous colonic surgery except for simple polypectomy.
- •18) History of cancer within the last 5 years other than resected cutaneous basal and squamous cell carcinomas, in situ cervical cancer and surgically removed colon polyps.
- •19) Women who are pregnant or breast feeding ;
- •20) Patients known to be seropositive for HIV, or who have had an AIDS defining illness, or a known immunodeficiency disorder
- •21) Patients with a history of tuberculosis or exposure to tuberculosis, or a history of a chest X ray suspicious for tuberculosis, unless shown to be PPD negative.
- •22) History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure;
- •23) Known allergy to plants of the Acanthaceae family;
- •24) Unwillingness to participate in the study;
- •25) Any underlying medical condition that in the Investigator’s opinion will make the administration of study drug hazardous to the patient or would obscure the interpretation of adverse events.
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Treatment with SA4503, 1 mg or 3 mg Once Daily for 8 Weeks, in Subjects With Major Depressive DisorderMajor Depressive Disorder (MDD)MedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSEUCTR2007-002740-16-FIM's Science Corporation150
进行中（未招募）
1 期
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Primary Sjögren's SyndromeEUCTR2016-000101-37-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO120
进行中（未招募）
1 期
A randomized, blinded clinical study comparing the combination durvalumab and olaparib to durvalumab alone for patients with advanced bladder cancernresectable Stage IV Urothelial CancerMedDRA version: 20.0Level: LLTClassification code 10022880Term: Invasive bladder cancer stage IVSystem Organ Class: 100000004864EUCTR2017-004556-27-ESAstraZeneca AB154
进行中（未招募）
1 期
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Primary Sjögren's Syndromesubjects with moderate to severe Sjögren's syndromeMedDRA version: 19.1Level: LLTClassification code 10040766Term: Sjogren's diseaseSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: LLTClassification code 10042846Term: Syndrome Sjogren'sSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: LLTClassification code 10040765Term: Sjogren'sSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: PTClassification code 10048676Term: Sjogren-Larsson syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-000101-37-GRBristol-Myers Squibb International Corporation160
招募中
不适用
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate theEfficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary Sjogren´s Syndrome-M350 Sicca syndrome [Sjogren]Sicca syndrome [Sjogren]M350PER-035-16BRISTOL MYERS SQUIBB COMPANY,1